Kombinationskemoterapi, Bevacizumab og/eller Atezolizumab til behandling af patienter med mangelfuld DNA-mismatch-reparation metastatisk kolorektal cancer, COMMIT-undersøgelsen
Kolorektal cancer metastatisk dMMR/MSI-H immunterapi (COMMIT)-undersøgelse: Et randomiseret fase III-studie af mFOLFOX6/Bevacizumab/Atezolizumab-kombination versus enkeltmiddel atezolizumab i førstelinjebehandlingen af patienter med mangelfuld DNA-mismatch-reparation (dMMR) Instabilitet-Høj (MSI-H) metastatisk tyktarmskræft
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Andet: Quality-of-Life Assessment
- Biologisk: Bevacizumab
- Medicin: Fluorouracil
- Procedure: Magnetic Resonance Imaging
- Andet: Questionnaire Administration
- Procedure: Biospecimen Collection
- Medicin: Atezolizumab
- Medicin: Oxaliplatin
- Procedure: Computed Tomography
- Medicin: Leucovorin
- Procedure: Positron Emission Tomography
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.
SECONDARY OBJECTIVES:
I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.
TRANSLATIONAL OBJECTIVE:
I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Kingman, Arizona, Forenede Stater, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Forenede Stater, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Anaheim, California, Forenede Stater, 92806
- Kaiser Permanente-Anaheim
-
Baldwin Park, California, Forenede Stater, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, Forenede Stater, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, Forenede Stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord, California, Forenede Stater, 94520
- John Muir Medical Center-Concord
-
Fontana, California, Forenede Stater, 92335
- Kaiser Permanente-Fontana
-
Harbor City, California, Forenede Stater, 90710
- Kaiser Permanente South Bay
-
Irvine, California, Forenede Stater, 92618
- Kaiser Permanente-Irvine
-
Los Angeles, California, Forenede Stater, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Forenede Stater, 90034
- Kaiser Permanente West Los Angeles
-
Marysville, California, Forenede Stater, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Forenede Stater, 95355
- Memorial Medical Center
-
Ontario, California, Forenede Stater, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Forenede Stater, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Forenede Stater, 92868
- Saint Joseph Hospital - Orange
-
Panorama City, California, Forenede Stater, 91402
- Kaiser Permanente - Panorama City
-
Riverside, California, Forenede Stater, 92505
- Kaiser Permanente-Riverside
-
Sacramento, California, Forenede Stater, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Forenede Stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Salinas, California, Forenede Stater, 93901
- Salinas Valley Memorial
-
San Diego, California, Forenede Stater, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Forenede Stater, 92108
- Kaiser Permanente-Rio San Diego
-
San Marcos, California, Forenede Stater, 92078
- Kaiser Permanente-San Marcos
-
Walnut Creek, California, Forenede Stater, 94598
- John Muir Medical Center-Walnut Creek
-
Whittier, California, Forenede Stater, 90602
- Presbyterian Intercommunity Hospital
-
Woodland Hills, California, Forenede Stater, 91367
- Kaiser Permanente-Woodland Hills
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Forenede Stater, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Forenede Stater, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Forenede Stater, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forenede Stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forenede Stater, 80920
- Memorial Hospital North
-
Denver, Colorado, Forenede Stater, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Forenede Stater, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Forenede Stater, 80204
- Denver Health Medical Center
-
Denver, Colorado, Forenede Stater, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Forenede Stater, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Forenede Stater, 80210
- AdventHealth Porter
-
Englewood, Colorado, Forenede Stater, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Forenede Stater, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, Forenede Stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forenede Stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, Forenede Stater, 80401
- National Jewish Health-Western Hematology Oncology
-
Greeley, Colorado, Forenede Stater, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Forenede Stater, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, Forenede Stater, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Forenede Stater, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Forenede Stater, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Forenede Stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Forenede Stater, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, Forenede Stater, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury, Connecticut, Forenede Stater, 06810
- Danbury Hospital
-
Hartford, Connecticut, Forenede Stater, 06102
- Hartford Hospital
-
Meriden, Connecticut, Forenede Stater, 06451
- Midstate Medical Center
-
New Britain, Connecticut, Forenede Stater, 06050
- The Hospital of Central Connecticut
-
Norwich, Connecticut, Forenede Stater, 06360
- William Backus Hospital
-
-
Delaware
-
Millville, Delaware, Forenede Stater, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Forenede Stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forenede Stater, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Forenede Stater, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20002
- Kaiser Permanente-Capitol Hill Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Forenede Stater, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Gainesville, Florida, Forenede Stater, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Forenede Stater, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Forenede Stater, 32803
- AdventHealth Orlando
-
-
Georgia
-
Albany, Georgia, Forenede Stater, 31701
- Phoebe Putney Memorial Hospital
-
Athens, Georgia, Forenede Stater, 30607
- University Cancer and Blood Center LLC
-
Augusta, Georgia, Forenede Stater, 30912
- Augusta University Medical Center
-
Augusta, Georgia, Forenede Stater, 30901
- Augusta Oncology Associates PC-D'Antignac
-
Augusta, Georgia, Forenede Stater, 30909
- Augusta Oncology Associates PC-Wheeler
-
Newnan, Georgia, Forenede Stater, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forenede Stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forenede Stater, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Forenede Stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forenede Stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forenede Stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forenede Stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Forenede Stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Forenede Stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forenede Stater, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Forenede Stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forenede Stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forenede Stater, 60612
- University of Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Forenede Stater, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forenede Stater, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Forenede Stater, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Forenede Stater, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Forenede Stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Forenede Stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Forenede Stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forenede Stater, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forenede Stater, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Forenede Stater, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Forenede Stater, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Forenede Stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Forenede Stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forenede Stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forenede Stater, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Forenede Stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forenede Stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
Washington, Illinois, Forenede Stater, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Forenede Stater, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Forenede Stater, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Forenede Stater, 46256
- Community Cancer Center North
-
Kokomo, Indiana, Forenede Stater, 46904
- Community Howard Regional Health
-
Lafayette, Indiana, Forenede Stater, 47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City, Indiana, Forenede Stater, 46360
- Woodland Cancer Care Center
-
Mooresville, Indiana, Forenede Stater, 46158
- Franciscan Health Mooresville
-
Terre Haute, Indiana, Forenede Stater, 47804
- Union Hospital
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forenede Stater, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Forenede Stater, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, Forenede Stater, 50036
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Forenede Stater, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Forenede Stater, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Forenede Stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Forenede Stater, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, Forenede Stater, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Forenede Stater, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forenede Stater, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Forenede Stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, Forenede Stater, 67601
- HaysMed
-
Lawrence, Kansas, Forenede Stater, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Forenede Stater, 66061
- The University of Kansas Cancer Center - Olathe
-
Salina, Kansas, Forenede Stater, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Forenede Stater, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Forenede Stater, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Forenede Stater, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Forenede Stater, 67214
- Cancer Center of Kansas - Wichita
-
-
Kentucky
-
Bardstown, Kentucky, Forenede Stater, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Forenede Stater, 40503
- Baptist Health Lexington
-
Lexington, Kentucky, Forenede Stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, Forenede Stater, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Forenede Stater, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Forenede Stater, 40217
- Norton Audubon Hospital and Medical Campus
-
-
Louisiana
-
Kenner, Louisiana, Forenede Stater, 70065
- Ochsner Medical Center Kenner
-
New Orleans, Louisiana, Forenede Stater, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Augusta, Maine, Forenede Stater, 04330
- Harold Alfond Center for Cancer Care
-
Bangor, Maine, Forenede Stater, 04401
- Eastern Maine Medical Center
-
Belfast, Maine, Forenede Stater, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Forenede Stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Forenede Stater, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, Forenede Stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forenede Stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, Forenede Stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21244
- Kaiser Permanente-Woodlawn Medical Center
-
Easton, Maryland, Forenede Stater, 21601
- University of Maryland Shore Medical Center at Easton
-
Gaithersburg, Maryland, Forenede Stater, 20879
- Kaiser Permanente-Gaithersburg Medical Center
-
Largo, Maryland, Forenede Stater, 20774
- Kaiser Permanente - Largo Medical Center
-
Lutherville, Maryland, Forenede Stater, 21093
- Kaiser Permanente Lutherville - Timonium Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana-Farber Cancer Institute
-
Lowell, Massachusetts, Forenede Stater, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, Forenede Stater, 48706
- McLaren Cancer Institute-Bay City
-
Bloomfield, Michigan, Forenede Stater, 48302
- McLaren Cancer Institute-Bloomfield
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, Forenede Stater, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forenede Stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forenede Stater, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Forenede Stater, 48346
- McLaren Cancer Institute-Clarkston
-
Clarkston, Michigan, Forenede Stater, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Forenede Stater, 48346
- Newland Medical Associates-Clarkston
-
Clinton Township, Michigan, Forenede Stater, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Forenede Stater, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Forenede Stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Forenede Stater, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Forenede Stater, 48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Jackson, Michigan, Forenede Stater, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Forenede Stater, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Forenede Stater, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Forenede Stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, Forenede Stater, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, Forenede Stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Forenede Stater, 48154
- Hope Cancer Clinic
-
Mount Clemens, Michigan, Forenede Stater, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, Forenede Stater, 48858
- McLaren Cancer Institute-Central Michigan
-
Novi, Michigan, Forenede Stater, 48377
- Henry Ford Medical Center-Columbus
-
Petoskey, Michigan, Forenede Stater, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, Forenede Stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Forenede Stater, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron, Michigan, Forenede Stater, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, Forenede Stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forenede Stater, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Forenede Stater, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Forenede Stater, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, Forenede Stater, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, Forenede Stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Forenede Stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Forenede Stater, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Forenede Stater, 55337
- Minnesota Oncology - Burnsville
-
Deer River, Minnesota, Forenede Stater, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Forenede Stater, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Forenede Stater, 55746
- Essentia Health Hibbing Clinic
-
Maplewood, Minnesota, Forenede Stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forenede Stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forenede Stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forenede Stater, 55454
- Health Partners Inc
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forenede Stater, 55102
- United Hospital
-
Sandstone, Minnesota, Forenede Stater, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Forenede Stater, 55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Grenada, Mississippi, Forenede Stater, 38901
- Baptist Cancer Center-Grenada
-
New Albany, Mississippi, Forenede Stater, 38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford, Mississippi, Forenede Stater, 38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven, Mississippi, Forenede Stater, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, Forenede Stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Saint Francis Medical Center
-
Columbia, Missouri, Forenede Stater, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Joplin, Missouri, Forenede Stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forenede Stater, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Forenede Stater, 64108
- University Health Truman Medical Center
-
St Louis, Missouri, Forenede Stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forenede Stater, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, Forenede Stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forenede Stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forenede Stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forenede Stater, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Forenede Stater, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Forenede Stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forenede Stater, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forenede Stater, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Forenede Stater, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Forenede Stater, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester, New Hampshire, Forenede Stater, 03104
- Dartmouth Cancer Center - Manchester/ DCC Manchester
-
Nashua, New Hampshire, Forenede Stater, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Hamilton, New Jersey, Forenede Stater, 08690
- The Cancer Institute of New Jersey Hamilton
-
Morristown, New Jersey, Forenede Stater, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, Forenede Stater, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Forenede Stater, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, Forenede Stater, 08876
- Robert Wood Johnson University Hospital Somerset
-
Summit, New Jersey, Forenede Stater, 07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Forenede Stater, 87110
- Presbyterian Kaseman Hospital
-
Las Cruces, New Mexico, Forenede Stater, 88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho, New Mexico, Forenede Stater, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
Elmira, New York, Forenede Stater, 14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Lake Success, New York, Forenede Stater, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Forenede Stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester
-
White Plains, New York, Forenede Stater, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton, North Carolina, Forenede Stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Forenede Stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Forenede Stater, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Forenede Stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kenansville, North Carolina, Forenede Stater, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Forenede Stater, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Forenede Stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, Forenede Stater, 28574
- ECU Health Oncology Richlands
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Broadway Medical Center
-
Grand Forks, North Dakota, Forenede Stater, 58201
- Altru Cancer Center
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44307
- Cleveland Clinic Akron General
-
Belpre, Ohio, Forenede Stater, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Forenede Stater, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Forenede Stater, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, Forenede Stater, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Forenede Stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Forenede Stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forenede Stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forenede Stater, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Forenede Stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Forenede Stater, 43228
- Doctors Hospital
-
Columbus, Ohio, Forenede Stater, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Forenede Stater, 43215
- Grant Medical Center
-
Columbus, Ohio, Forenede Stater, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Forenede Stater, 45409
- Miami Valley Hospital
-
Delaware, Ohio, Forenede Stater, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Forenede Stater, 43015
- Grady Memorial Hospital
-
Kettering, Ohio, Forenede Stater, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Forenede Stater, 43130
- Fairfield Medical Center
-
Mansfield, Ohio, Forenede Stater, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mansfield, Ohio, Forenede Stater, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Forenede Stater, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Forenede Stater, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Forenede Stater, 44124
- Hillcrest Hospital Cancer Center
-
Mount Vernon, Ohio, Forenede Stater, 43050
- Knox Community Hospital
-
Newark, Ohio, Forenede Stater, 43055
- Licking Memorial Hospital
-
Portsmouth, Ohio, Forenede Stater, 45662
- Southern Ohio Medical Center
-
Sandusky, Ohio, Forenede Stater, 44870
- North Coast Cancer Care
-
Sylvania, Ohio, Forenede Stater, 43560
- ProMedica Flower Hospital
-
Warrensville Heights, Ohio, Forenede Stater, 44122
- South Pointe Hospital
-
West Chester, Ohio, Forenede Stater, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westerville, Ohio, Forenede Stater, 43081
- Saint Ann's Hospital
-
Zanesville, Ohio, Forenede Stater, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton, Oklahoma, Forenede Stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forenede Stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Tulsa, Oklahoma, Forenede Stater, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Bend, Oregon, Forenede Stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forenede Stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forenede Stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Forenede Stater, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Forenede Stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Forenede Stater, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Forenede Stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forenede Stater, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Forenede Stater, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Forenede Stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Forenede Stater, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton, Pennsylvania, Forenede Stater, 18045
- Saint Luke's Hospital-Anderson Campus
-
Erie, Pennsylvania, Forenede Stater, 16544
- Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Forenede Stater, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Jefferson Hills, Pennsylvania, Forenede Stater, 15025
- Jefferson Hospital
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- Forbes Hospital
-
Natrona Heights, Pennsylvania, Forenede Stater, 15065
- Allegheny Valley Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- UPMC Hillman Cancer Center
-
Quakertown, Pennsylvania, Forenede Stater, 18951
- Saint Luke's Hospital-Quakertown Campus
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Forenede Stater, 15090
- Wexford Health and Wellness Pavilion
-
Willow Grove, Pennsylvania, Forenede Stater, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Anderson, South Carolina, Forenede Stater, 29621
- AnMed Health Cancer Center
-
Beaufort, South Carolina, Forenede Stater, 29902
- Beaufort Memorial Hospital
-
Boiling Springs, South Carolina, Forenede Stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Forenede Stater, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forenede Stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forenede Stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Forenede Stater, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Forenede Stater, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Forenede Stater, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Forenede Stater, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Aberdeen, South Dakota, Forenede Stater, 57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Bristol, Tennessee, Forenede Stater, 37620
- Bristol Regional Medical Center
-
Collierville, Tennessee, Forenede Stater, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Cookeville, Tennessee, Forenede Stater, 38501
- Cookeville Regional Medical Center
-
Johnson City, Tennessee, Forenede Stater, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, Forenede Stater, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Forenede Stater, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Memphis, Tennessee, Forenede Stater, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Amarillo, Texas, Forenede Stater, 79106
- The Don and Sybil Harrington Cancer Center
-
Beaumont, Texas, Forenede Stater, 77701
- Baptist Hospitals of Southeast Texas Cancer Center
-
Conroe, Texas, Forenede Stater, 77384
- UT MD Anderson - The Woodlands
-
Dallas, Texas, Forenede Stater, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Forenede Stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Edinburg, Texas, Forenede Stater, 78539
- STCC at DHR Health Institute for Research and Development
-
Houston, Texas, Forenede Stater, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, Forenede Stater, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Forenede Stater, 77030
- Houston Methodist Hospital
-
Houston, Texas, Forenede Stater, 77079
- UT MD Anderson - West Houston
-
League City, Texas, Forenede Stater, 77573
- UT MD Anderson - League City
-
Port Arthur, Texas, Forenede Stater, 77642
- Baptist Regional Cancer Network-Cancer Center of Southeast Texas
-
Sugar Land, Texas, Forenede Stater, 77478
- UT MD Anderson - Sugar Land
-
Temple, Texas, Forenede Stater, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury, Vermont, Forenede Stater, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Bristol, Virginia, Forenede Stater, 24201
- Ballad Health Cancer Care - Bristol
-
Burke, Virginia, Forenede Stater, 22015
- Kaiser Permanente-Burke Medical Center
-
Fishersville, Virginia, Forenede Stater, 22939
- Augusta Health Center for Cancer and Blood Disorders
-
Lynchburg, Virginia, Forenede Stater, 24501
- Centra Alan B Pearson Regional Cancer Center
-
McLean, Virginia, Forenede Stater, 22102
- Kaiser Permanente Tysons Corner Medical Center
-
Norton, Virginia, Forenede Stater, 24273
- Ballad Health Cancer Care - Norton
-
Richmond, Virginia, Forenede Stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forenede Stater, 23229
- Virginia Cancer Institute
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Forenede Stater, 23970
- VCU Community Memorial Health Center
-
Woodbridge, Virginia, Forenede Stater, 22192
- Kaiser Permanente-Caton Hill Medical Center
-
-
Washington
-
Edmonds, Washington, Forenede Stater, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, Forenede Stater, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, Forenede Stater, 98368
- Jefferson Healthcare
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center-First Hill
-
Spokane, Washington, Forenede Stater, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Forenede Stater, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Forenede Stater, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Antigo, Wisconsin, Forenede Stater, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, Forenede Stater, 54911
- ThedaCare Regional Cancer Center
-
Appleton, Wisconsin, Forenede Stater, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, Forenede Stater, 54806
- Duluth Clinic Ashland
-
Brookfield, Wisconsin, Forenede Stater, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Franklin, Wisconsin, Forenede Stater, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Green Bay, Wisconsin, Forenede Stater, 54301
- Bellin Memorial Hospital
-
Janesville, Wisconsin, Forenede Stater, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Johnson Creek, Wisconsin, Forenede Stater, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Forenede Stater, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Medford, Wisconsin, Forenede Stater, 54451
- Aspirus Medford Hospital
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Forenede Stater, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Forenede Stater, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forenede Stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Forenede Stater, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander, Wisconsin, Forenede Stater, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Forenede Stater, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Forenede Stater, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Forenede Stater, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forenede Stater, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Wyoming
-
Cheyenne, Wyoming, Forenede Stater, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Forenede Stater, 82414
- Billings Clinic-Cody
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial
-
Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible
-
Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1
-
No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass
-
Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)
-
Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)
-
Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)
-
Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)
-
Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)
-
A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:
- The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
- A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
- Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
-
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results
-
Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
-
Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period
Exclusion Criteria:
-
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
-
Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
-
Documented New York Heart Association (NYHA) class III or IV congestive heart failure
-
Serious or non-healing wound, skin ulcer, or bone fracture
-
History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high
-
Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin
-
Known DPD (dihydro pyrimidine dehydrogenase) deficiency
-
Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)
-
Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization
-
History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:
- Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
- No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
-
Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,
- Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
-
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,
-
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
-
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
-
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
-
History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
Patients with known active tuberculosis (TB) are excluded
-
Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Signs or symptoms of infection within 14 days prior to randomization
-
Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
-
The administration of a live, attenuated vaccine within 28 days prior to randomization
-
Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Arm I (bevacizumab, mFOLFOX6)
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL) |
Ancillary studies
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo collection of blood samples
Andre navne:
Given IV
Andre navne:
Undergo CT or CT/PET
Andre navne:
Given IV
Andre navne:
Undergo CT/PET
Andre navne:
|
|
Eksperimentel: Arm II (atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo collection of blood samples
Andre navne:
Given IV
Andre navne:
Undergo CT or CT/PET
Andre navne:
Undergo CT/PET
Andre navne:
|
|
Eksperimentel: Arm III (atezolizumab, bevacizumab, mFOLFOX6)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo collection of blood samples
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo CT or CT/PET
Andre navne:
Given IV
Andre navne:
Undergo CT/PET
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression free survival (PFS)
Tidsramme: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted. |
From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sats af PFS
Tidsramme: Ved 12 måneder
|
Ved 12 måneder
|
|
|
Overall survival (OS)
Tidsramme: The time from randomization to death from any cause, assessed up to 5 years
|
Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
The time from randomization to death from any cause, assessed up to 5 years
|
|
Objective response rate (ORR) (complete response [CR] or partial response [PR])
Tidsramme: Up to 5 years
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
Up to 5 years
|
|
Incidence of adverse events
Tidsramme: Up to 30 days after last cycle
|
Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population. |
Up to 30 days after last cycle
|
|
Disease control rate (CR + PR + stable disease [SD])
Tidsramme: At 12 months
|
Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
At 12 months
|
|
Duration of overall response (CR or PR)
Tidsramme: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
|
Duration of SD
Tidsramme: From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of fatigue
Tidsramme: At 16 weeks
|
Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Physical functioning
Tidsramme: At 16 weeks
|
Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Health utility scores
Tidsramme: Up to 5 years
|
Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. |
Up to 5 years
|
|
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy dependent on the number of somatic mutations
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy in tumors with MLH1 silencing
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Tidsramme: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
Development of progression or relapse to treatment in cfDNA
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
Tidsramme: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
PFS of patients with high levels of diversity
Tidsramme: Up to 5 years
|
Compared to patients with low levels of diversity. Will use the ITT population. |
Up to 5 years
|
|
Change in T-cell diversity
Tidsramme: Baseline to first restaging between immunotherapy arms and the standard of care arm
|
Will use the ITT population. |
Baseline to first restaging between immunotherapy arms and the standard of care arm
|
|
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
Tidsramme: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Caio Max S Rocha Lima, NRG Oncology
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- Kolorektale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Enzymer og coenzymer
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Koordinationskomplekser
- Pyrimidiner
- Kemiteknikker, analytisk
- Spektrumanalyse
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folinsyre
- Pterins
- Pteridiner
- Uracil
- Pyrimidinoner
- Coenzymer
- Immunoglobulin -isotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Oxaliplatin
- Bevacizumab
- Fluorouracil
- Leucovorin
- Immunoglobulin G
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Disulfider
- atezolizumab
- Dehydroftorafur
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2016-01961
- U10CA180868 (U.S. NIH-bevilling/kontrakt)
- NCI-2016-01961 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- NRG-GI004/S1610
- NRG-GI004 (Anden identifikator: CTEP)
- NRG-GI004 (Anden identifikator: NRG Oncology)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .